📈CJC-1295
Long-acting GHRH analogue. Stimulates pituitary GH release in pulses. Combined with Ipamorelin for synergistic GH secretion. DAC (Drug Affinity Complex) extends half-life from 30 min to 6–8 days.
GHRH analogue with DAC technologyWhat Is CJC-1295?
CJC-1295 is a tetrasubstituted analogue of GHRH(1-29) with additional modifications including a Drug Affinity Complex (DAC) — a maleimide-modified lysine that covalently binds serum albumin, extending half-life from ~30 minutes to 6–8 days. It stimulates pituitary GH release by binding GHRHR.
Key Mechanisms
- GHRHR agonism — stimulates pituitary somatotroph cells to release GH in physiological pulses
- Sustained GH elevation — DAC technology enables once-weekly dosing while preserving pulsatile release
- IGF-1 induction — elevated GH drives hepatic IGF-1 production via JAK2/STAT5b
Stacking
Most commonly combined with Ipamorelin — CJC-1295 amplifies GH pulse amplitude (GHRH pathway) while Ipamorelin increases GH pulse frequency (GHSR/ghrelin pathway) without cortisol/prolactin elevation.
Key References
- Teichman SL et al. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295." J Clin Endocrinol Metab, 2006;91:799–805.
Frequently Asked Questions
Drug Affinity Complex — a maleimide-modified lysine that covalently binds to circulating albumin, which is what extends the peptide's functional half-life from about 30 minutes (unmodified GHRH) to roughly 6–8 days.
No. "CJC-1295" refers to the long-acting, DAC-modified version. The shorter-acting variant sometimes sold as "CJC-1295 without DAC" is more accurately labelled Modified GRF (1-29) — a related but distinct research peptide with a much shorter half-life.
They act on two separate GH-release pathways — the GHRH receptor (CJC-1295) and the ghrelin/GHSR-1a receptor (Ipamorelin) — so combining them is studied as a way to amplify both the amplitude and frequency of GH pulses.